28 October 2011: CBio Limited (ASX:CBZ) is pleased to announce...

28 October 2011: CBio Limited (ASX:CBZ) is pleased to announce that its research “Recombinant chaperonin10 (XToll) suppresses cutaneous lupus and lupus nephritis in MRL-(Fas)lpr mice” is now published on the advanced access site of the Oxford Journals publication, Nephrology Dialysis Transplantation.



In CBio’s study, treatment of mice with XToll entirely prevented cutaneous lupus. XToll also significantly suppressed nephritis in the kidneys, and significantly prolonged life span. In humans, nephritis in the kidneys is a major cause of mortality and shortened life span of patients with lupus.



XToll also reduced the levels of pro-inflammatory cytokines such as IL-6 and TNF-alpha, a finding consistent with data from the company’s phase IIa rheumatoid arthritis clinical trial.



This research indicates that in addition to rheumatoid arthritis, XToll could have utility in the treatment of human lupus, either alone or as part of a drug combination therapy. It is estimated the lupus market will be worth $2.5 billion per annum by 2017........{Hey DR. Craven do you have a problem with EFFICACY.... THE Above is very positive but in the News Letter to Share Holders you state,, "The efficacy in an animal model does not necessarilly Guarantee effectiness in HUMANS.. I THOUGHT that PR. issue was solved....Why the hell are you adding negative Phrases to VERY POSITIVE Anns....